Royalty Report: Drugs, cardiac, Disease – Collection: 240469

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 18

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 18

Primary Industries

  • Drugs
  • cardiac
  • Disease
  • Therapeutic
  • Diagnostic
  • Enzymes
  • Pharmaceuticals
  • Biotechnology
  • Drug Discovery
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 240469

License Grant
This amendments revises the intellectual property, royalties and identifies potential options to be exercised.  This agreement is for enoximone property and processes.
License Property
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.

The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.

Field of Use
Licensee is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders.

IPSCIO Record ID: 240577

License Grant
Licensor grants the exclusive right and license under the Intellectual Property and Know How to make, have made, use, lease, sublicense and sell the Licensed Products, and to practice the Licensed Processes in the Territory for the Field of Use.
License Property
Licensor is the owner of certain University of Colorado intellectual property, embodied in inventions, patent rights, patents, patent applications, copyrights or proprietary Know-How (as later defined herein and referred to collectively as Intellectual Property Rights, related to six separate invention disclosures.

The invention disclosures are Angiotention-Converting Enzyme Genetic Variant Screen; Transgenic Mouse Over-Expressing the Human Beta-1 Adrenergic Receptor A Screening Tool for New Heart Failure Therapeutic Agents; Transgenic Model for Heart Failure; Method for ldentifying Adrenergic Receptor Antagonists Having Good Tolerability; Diagnosis and Treatment of Myocardial Failure; and, Method of Treating Heart Failure Using Enoximone and Metoprolol.

Field of Use
The Field of Use shall mean human heart disease diagnosis, prevention and therapy.

IPSCIO Record ID: 260445

License Grant
The Parties entered into the License Agreement under which Licensee obtained an exclusive worldwide license under the Licensor Patents, Licensor Knowhow and Joint Patents to develop and commercialize Enoximone.  Licensor also transferred any and all of Licensors rights under the existing Licensors Trademarks in several countries around the world, including the United Kingdom and the Benelux countries.

With the First Amendment to the License Agreement  under which Licensee granted to Licensor the right to co-market the Product containing the oral form of Enoximone (Oral Enoximone) in Europe. This grant was terminated under the Second Amendment to the License Agreement.

The Second Amendment provided for a certain royalty to be paid by Licensee to Licensor in the event the Net Sales of Oral Enoximone in Europe reached or exceeded the threshold set forth in the amendment.

Licensor was acquired by a pharmaceutical company organized under the laws of France.  

The Parties acknowledge and agree that the License Agreement only obligates Licensee to pay Licensor royalties on Net Sales of Perfan i.v. in the Limited European Countries. The Agreement does not obligate Licensee to pay royalties on the Net Sales of Oral Enoximone in the Limited European Countries. The Parties further acknowledge and agree that the License Agreement, as amended and restated, only concerns and relates to the sale of any Product, including Perfan i.v. and Oral Enoximone, in any Territory other than Europe, and only concerns and relates to the sale of any Additional Product  in the Limited European Countries.

Licensor transfer of the Licensor Trademarks in the United Kingdom and the Benelux countries of Belgium, the Netherlands and Luxembourg, is perpetual and irrevocable, as of the Effective Date of the Third Amendment.

License Property
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.

Perfan® I.V. is an intravenous (i.v.) formulation of enoximone.

Field of Use
Enoximone capsules for the treatment of patients with advanced chronic heart failure.

IPSCIO Record ID: 263953

License Grant
For the Patent and Know-how License to Conduct Development, Licensor grants an exclusive license, even as to Licensor and its Affiliates, under the Licensor Patents and Licensor Know-how, and Joint Patents, if any, to conduct Development in the Territory in accordance with the terms of this Agreement with respect to Enoximone for use in the Field.

For Commercialization, Licensor grants an exclusive, even as to Licensor and its Affiliates, license under the Licensor Patents and Licensor Know-how to conduct manufacturing, pre-marketing activities, commercialization, including the right to make, have made, use, import, sell, offer for sale and have sold, and related activities in the Territory with respect to Enoximone and any Product in accordance with the terms of this Agreement.

License Property
Enoximone shall mean 1,3-dihydro-4-methyl-5-[ 4-(methythio )-benzoyl]-2Himidazol-2-one, and all pharmaceutically-acceptable forms (e.g., salts) and all formulations thereof.

Licensor Patent means any and all Patents which cover the discovery, evaluation, manufacture, use or importation, offer for sale and/or sale of Enoximone in the Field or Product, which Patent is owned or Controlled by Licensor or any of its Affiliates, including Licensors or any of its Affiliates interest in any Joint Patent.

Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.

TITLE ENHANCEMENT OF PRAZOSIN

ABSTRACT THIS INVENTION RELATES TO THE SYNERGISTIC ENHANCEMENT OF CERTAIN ANTIHYPERTENSIVES BY THE CONJUNCTIVE USE OF CERTAIN CARDIOTONIC AGENTS. MORE SPECIFICALLY, THIS INVENTION RELATES TO THE ENHANCEMENT OF THE BLOOD PRESSURE LOWERING EFFECT ACHIEVED WITH ALPHAl-ADRENOCEPTOR ANTAGONISTS BY THE CONJUNCTIVE ADMINISTRATION OF CARDIOTONIC AGENTS POSSESSING THE ABILITY TO SPECIFICALLY

Field of Use
The Field means the prevention, treatment and/ or diagnosis of cardiovascular diseases and disorders.

IPSCIO Record ID: 383605

License Grant
This license with the Collaboration and Option Agreement, is to license exclusively one or more of the Development Candidates for development and commercialization in the Licensed Field and in the Territory.

Licensor grants the exclusive, with the right to sublicense, under the Licensor Patents and the Licensor Know-How and in the Licensed Field, to research and have researched, develop and have developed, make and have made, and use and have used the Development Candidate and to research and have researched, develop and have developed, make and have made, manufacture and have manufactured, use and have used, market and have marketed, distribute and have distributed, sell and have sold, export and import for sale, and have exported or imported for sale, Drug Products in each country in the Territory.

License Property
HDAC shall mean any histone deacetylase protein.

HDAC Inhibitor Compound shall mean any Active Compound that has a specific, desired therapeutic action through its ability to bind directly to an HDAC and inhibit HDAC activity.

IC50 shall mean the concentration of a compound that reduces activity of an enzyme by 50% in a standard, validated assay.

Field of Use
The right relates to new histone deacetylase inhibitor (“HDACi”) product candidates developed through the collaboration for treating cardiac hypertrophy and heart failure.

The Cardiac Field shall mean the research, treatment, prognosis, diagnosis, prophylaxis, and monitoring of heart muscle disease.

IPSCIO Record ID: 28537

License Grant
German SubLicensee wishes to acquire SubLicensor's rights to commercialize and sell the Product and in connection therewith SubLicensor and SubLicensee have entered into that certain Stock Purchase Agreement effective as of January 1, 2006 which contemplates the purchase by SubLicensee of all of the outstanding capital stock of SubLicensor's wholly-owned subsidiary.
License Property
SubLicensor is a biotechnology company that has expertise and experience in the research and development of compounds for use in treating cardiovascular disease.

SubLicensor has obtained in a separate license agreeement an exclusive worldwide License (patents and know-how) to develop and commercialize Enoximone and all of rights under certain existing trademarks relating to Enoximone in several countries around the world.
Know-How License to Sublicensee for Commercialization. Upon the terms and subject to the conditions of this Agreement and the License Agreement, including, without limitation, the payment obligations herein, SubLicensor grants to Sublicensee an exclusive (even as to SubLicensor and its Affiliates) license under the SubLicensor Know-How to conduct Manufacturing, pre-marketing activities, Commercialization (including the right to make, have made (subject to Article 2.3), use, import (subject to Article 2.3), sell, offer for sale and have sold) and related activities in the Territory with respect to the Product in accordance with the terms of this Agreement.

Know-How License to Conduct Regulatory Approvals. Upon the terms and subject to the conditions of this Agreement and the License Agreement, including, without limitation, the payment obligations herein, SubLicensor grants to Sublicensee an exclusive license (even as to SubLicensor and its Affiliates) under the SubLicensor Know-How to conduct the Regulatory Approvals in the Territory in accordance with the terms of this Agreement with respect to the Product for use in the Field.

'Product' means that intravenous formulation of Enoximone for use in the Field marketed under the Trademarks. 'Enoximone' means 1,3-dihydro-4-methyl-5-[4-(methythio)-benzoyl]-2H-
imidazol-2-one, and all pharmaceutically-acceptable forms (e.g., salts) and all formulations thereof.

Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.

Field of Use
'Field' means the prevention, treatment and/or diagnosis of cardiovascular diseases and disorders.

IPSCIO Record ID: 203375

License Grant
The Licensors grant an exclusive license under Licensed Subject Matter to discover, research, develop, make, have made, use, offer for sale, sell and import licensed products and identified products within Licensed Territory for use within Licensed Field to
– Publish the general scientific findings from research related to Licensed Subject Matter and Licensed Products subject to the confidentiality terms, and
– Use Licensed Subject Matter or Identified Products solely for research, teaching and other educationally-related, non-commercial purposes only.
License Property
The patents are for Transgenic Animal Models for Cardiac hypertrophy and Methods and Use Thereof, Transgenic Animal Models for Cardiac hypertrophy and Methods and Use Thereof,  Transgenic Animal Models for Cardiac hypertrophy and Methods and Use Thereof and Methods and Compositions for Therapeutic Intervention in Cardiac Hypertrophy.

Licensed Product means any compound, assay, method, reagent, technology, or product comprising Licensed Subject Matter pursuant to this Agreement.

Licensed Subject Matter means inventions and discoveries claimed in Patent Rights or covered by Technology Rights within Licensed Field.

Technology Rights means Licensors rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols, techniques, software, designs, drawings or data created by Inventors relating to Licensed Subject Matter which are not covered by Patent Rights, but useful.

Field of Use
Licensed Field means the discovery, development, manufacture, use, sale, offer for sale, and import of pharmaceutical, biologic, gene therapy and/or health care products for the treatment, prevention and/or diagnosis of cardiac hypertrophy and heart failure by inhibition of calcineurin activity and calmodulin-dependent protein activity, and NFAT activity; the development, manufacture and use of assays for the identification of pharmaceutical and/or biologic agents for the treatment, prevention, and/or diagnosis of cardiac hypertrophy and heart failure by inhibition of calcineurin activity and calmodulin-dependent protein activity, and NFAT activity; and the development, manufacture and use of assays useful in the diagnosis of, prognosis of, or determination of predisposition to, cardiac hypertrophy and heart failure by inhibition of calcineurin activity and calmodulin-dependent protein activity, and NFAT activity.

IPSCIO Record ID: 273380

License Grant
The University, with permissions as applicable, grant an exclusive, sublicensable license for the field of Use in the Territory to
—  practice under the Patent Rights
—  make, have made, use, lease, import, export and/or sell Licensed Products,
—  sell, use and/or practice Licensed Services.

The University grants a non-exclusive license to use Know-how for the Field of Use in the territory to
—  make, have made, use, lease and/or sell Licensed Products
—  sell, use and/or practice Licensed Services.

License Property
The University has rights to patents titles Reactive Oxygen Generating Enzyme and Inhibitor with Nitric Oxide Bioactivity and Uses Thereof, and, Composition for the Treatment and Prevention of Heart Disease and Methods of Using the Same.

The Phase II candidate and all other drugs in the portfolio are designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. All have a dual mechanism of action of inhibiting the creation of reactive oxygen radicals and concurrently providing nitric oxide in the failing heart. The therapeutic target is the ryanodine receptor, the ion channel in the heart that provides the calcium necessary for the heart to beat. The investigational drugs are believed to improve calcium cycling in the heart by acting on the ryanodine receptor to significantly improve the efficiency of heart contractility.

Field of Use
The field of use means all therapeutic uses for allopurinol, oxypurinol, ptcein-6-aldehyde and mixtures thereof, that are provided with a nitrate group thereon, as well as therapeutic uses for any combinations of these agents with nitrates or other NO donors.

The drug portfolio is to develop and commercialize certain of Licensee's proprietary cardiovascular drugs to treat heart failure.

IPSCIO Record ID: 240578

License Grant
The University grants a worldwide, exclusive license under Licensed Subject matter to discover, research, develop, make, have made, use offer for sale, sell and import Licensed Products and Identified Products for use within Licensed Field.
License Property
Licensed Product means any compound, assay, method, reagent, technology, product or service comprising Licensed Subject Matter.

Licensed Subject Matter means inventions, discoveries, assays and processes covered by Patent Rights and/or Technology Rights within Licensed Field.

The patents are for Methods and Compositions Relating to Muscle Selective Calcineurin Interacting Protein (MCIP).

Field of Use
Licensed field means treatment, prevention, diagnosis and/or prognosis of cardiac hypertrophy, heart disease and heart failure; and determination of predisposition to cardiac hypertrophy, heart disease and heart failure.

IPSCIO Record ID: 328142

License Grant
The University grants
–  an exclusive license to make, have made, use, sell, offer to sell and import the Know-How in the Territory and within the Fields of Use; and,
–  an exclusive license of University’s Patent Rights, except for Patent Rights in University Case No. 2002.026H, in the Territory to make, have made, use, sell, offer to sell, and import any Licensed Products in the Fields of Use and to practice any Licensed Processes in the Fields of Use; and
–  an exclusive license of University’s Patent Rights in University Case No. 2002.026H in the Territory to make, have made, use, sell, offer to sell and import any Licensed Products in the Fields of Use and to practice any Licensed Process in the Fields of Use.
License Property
Licensor has rights to technology relating to expression profiling in the intact human heart and a method of treating heart failure with bucindolol.

Bucindolol means the beta-adrenergic–receptor antagonist having the chemical formula 2-{2-hydroxy-
3{{2-(3-indolyl)-1,1-dimethylethyl}amino}propoxy}-benzonitrile hydrochloride, and its racemates, isomers, prodrugs, active metabolites, analogs and any pharmaceutically acceptable salt or complex thereof, and diagnostics used in connection with its prescription.

Bucindolol Invention shall mean an Invention relating solely to the use of Bucindolol as a therapeutic or as a diagnostic used solely in connection with the development of Bucindolol.

Patents are titled
Expression Profiling in the Intact Human Heart,
Methods for Treating Heart Failure with Bucindolol Based on Genetic Targeting of the Alpha-le Adrenergic
     Receptor,
Methods for Treating Heart Failure with Bucindolol Based on Genetic Targeting of the Beta-1 Adrenergic
     Receptor, and,
Methods for Treatment with Bucindolol Based on Genetic Targeting.

Field of Use
Fields of use is all fields.

Licensee is focused on developing and commercializing genetically-targeted therapies for heart failure and other cardiovascular diseases.

IPSCIO Record ID: 286018

License Grant
The Licensee and the University amended the terms for the royalty and milestone payments for the Licensed Product or Identified Product outlined in the original agreement.
License Property
Licensed Product means any compound, assay, method, reagent, technology, product or service comprising Licensed Subject Matter.

Identified Product means any product, or derivative thereof, which product or derivative is not covered by Patent Rights but either (a) elicits a positive response in technologies covered by Patent Rights, or (b) was identified, selected, or found to be useful, in whole or in part, through the use of one or more technologies (including, but not limited to assays, methods, and/or reagents) covered by Patent Rights. For greater certainty, the parties acknowledge and agree that Identified Products are not Licensed Products.

Licensed Subject Matter means inventions, discoveries, assays and processes covered by Patent Rights and/or Technology Rights within Licensed Field. The patents are for Methods and Compositions Relating to Muscle Selective Calcineurin Interacting Protein (MCIP).

Field of Use
Licensed field means treatment, prevention, diagnosis and/or prognosis of cardiac hypertrophy, heart disease and heart failure; and determination of predisposition to cardiac hypertrophy, heart disease and heart failure.

IPSCIO Record ID: 28064

License Grant
University granted the Licensee an exclusive United States and worldwide license under the patent rights for cardiac disorders.
License Property
Patent shall mean U.S. patent application Serial No.  09/186,755  and PCT application PCT/US98/23878, each filed on 11/5/98; EPO application filed 08/0212000; all assigned to the University entitled Methods for Treatment of Disorders of Cardiac Contractility. Invention entitled Xanthine Oxidase Inhibitors as Calcium-Sensitizing Therapeutic Agents for Heart Failure.
Field of Use
The Licensed Field shall mean therapeutic, diagnostic and commercial use of xanthine oxidase inhibitors for cardiovascular and neuromuscular disease.

IPSCIO Record ID: 183006

License Grant
In February 2017, the parties agreed to exercise the option to co-invest in the Phase 3 development program of omecamtiv mecarbil.

In December 2006, the Parties entered into a collaboration and option agreement to discover, develop and commercialize novel small molecule therapeutics, including omecamtiv mecarbil,  The agreement granted an option to obtain an exclusive license worldwide, except Japan, to develop and commercialize omecamtiv mecarbil and other drug candidates arising from the collaboration.  

In June 2013, the parties  executed an amendment to include Japan, resulting in a worldwide collaboration.   Under the Amendment, Parties conducted a Phase 1 pharmacokinetic study intended to support inclusion of Japan in a potential Phase 3 clinical development program and potential global registration dossier for omecamtiv mecarbil.

License Property
Omecamtiv mecarbil is a cardiac muscle myosin activator used to activate cardiac muscle contractility for potential applications in the treatment of heart failure.  This has a potential oral administration.
Field of Use
The Licensor / Collaborator is a late-stage biopharmaceutical company focused on the discovery and developments of first-in-class muscle activators as potential treatment for debilitating diseases in which muscle performance is compromised and/or declining.

IPSCIO Record ID: 7466

License Grant
The Licensor, government public health organization, hereby grants and Licensee accepts, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
Development and commercialization of this technology will provide treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion and inflammation of the cardiovascular system. Development and commercialization of this technology will also provide treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.
Field of Use
Fields of Use of the Licensed Property is for prevention, treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion, inflammation of the cardiovascular system and the treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.

IPSCIO Record ID: 359108

License Grant
Canadian Licensor granted Licensee the sole, exclusive, irrevocable license to patented nanotechnologies for use with any drugs including cannabinoids,  to develop and optimize a proprietary nanoformulation of pharmaceutical cannabidiol, designed to avoid first-pass metabolism and improve bioavailability, for the treatment of heart failure.
License Property
Nanotechnologies are designed to improve solubilization, pharmacokinetics, and drug targeting of lipophilic drugs. Nanotechnologies is the use of matter on an atomic, molecular, and supramolecular scale for industrial purposes.

Cannabidiol is a non-psychoactive molecule with broad therapeutic potential in the treatment of chronic inflammatory disease including heart failure.

Field of Use
The license to patented nanotechnologies is for use with any drugs or classes of drugs currently used or developed in the future to diagnose or treat heart failure and/or any cardiovascular disease and/or cardiopulmonary disease and/or cardiac arrhythmias.

Field of use to treat cardiovascular disease, cardiopulmonary disease, and cardiac arrhythmias.

IPSCIO Record ID: 240585

License Grant
The Parties have agreed to collaborate together in order to develop, improve, and commercialize therapeutics for the treatment of cardiovascular disease based upon Licensors proprietary technology.

Licensor, an individual, grants an exclusive, worldwide right and license during the term of this Agreement under all of Licensors rights in the Patent Rights and Technical Information to make, have made, use, have used, sell, have sold, and import, Collaboration Products.

License Property
Licensor has developed certain proprietary technology related to the combination of hydralazine and isosorbide dinitrate for the treatment of cardiovascular disease.

The patent is for Method of Reducing Mortality Associated with Congestive Heart Failure Using 1-Hydralazine and Isosorbide Dinitrate.

Field of Use
The field shall mean the combination of hydralazine and isosorbide dinitrate, with or without one or more additional active ingredients for the treatment of cardiovascular diseases.

IPSCIO Record ID: 26771

License Grant
We entered into a collaborative research.
License Property
Transaction is a research and license agreement using the licensor's technology involving a surface enhanced laser desorption/ionization system ('SELDI,' a technology described in United States Patent Application 08/068,896 and Patent No. 5,719,060 and U.S. Patent 6,225,047) along with certain related know-how and capacities that are uniquely enabling in the investigation of biomarkers.

These biomarkers are to be used biomarkers for diagnostic or therapeutic uses in the treatment of preeclampsia/ toxemia.

Pre-eclampsia or preeclampsia is a medical condition characterized by high blood pressure and significant amounts of protein in the urine of a pregnant woman.

Toxemia is a generic term for the presence of toxins in the blood.

IPSCIO Record ID: 28172

License Grant
The Licensor, a nonprofit American academic medical center, grants to the Belgium Licensee an exclusive license to make, have made, use, modify, enhance, promote, market and/or sell the Licensed Invention whether or not patented, and a non-exclusive right to use the Licensed Know-How, in the Territory within the Field of Heart Disease.
The Licensee may assigning or subcontract the rights with permission from the Licensor.
License Property
Licensed inventions means Cardiogenic Cocktail for the production of Cardiac Cells and Stem Cell Based Therapy for Non-ischemic Cardiomyopathic Heart Failure.

2004-182 Derivation of a Cardiopoetic Cellular Phenotype from a Stem Cell Source.

And the related Patents and Patent Applications;

06/592,871 Stem Cells and treatment of Vascular Tissue

06/680,775 Treating Cardiovascular Tissue

06/832,845 Methods and Materials for providing Cardiac Cells

PCT/US2005/026800 Treating Cardiovascular Tissue

PCT/US2008/064895 Methods and Materials for using Cells to treat Heart Tissue

PCT/US2009/044714 Compositions and Methods for Using Cells to treat Heart Tissue

PCT/US2009/044751 Methods for determining the Cardio Generative Potential of Mammalian Cells

3. Paragraph 2.02 is replaced with the following;

Field of Use
FIELD OF USE means cardiovascular regeneration or protection.

Field of Use means treatment of embryonic and autologus mesenchymal stem cells to guide development into cardiomyocytes for the treatment of myocardial infarction, ischemic heart disease, ischemic and non-ischemic cardiomyopathy.

The Belgian biopharma company is involved in the discovery, development and commercialisation of regenerative and protective therapies for the treatment of cardiac diseases.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.